CRVS
Corvus Pharmaceuticals, Inc. NASDAQ Listed Mar 23, 2016$14.59
Mkt Cap $1.2B
52w Low $3.17
48.0% of range
52w High $26.95
50d MA $15.56
200d MA $10.68
P/E (TTM)
-81.4x
EV/EBITDA
-14.1x
P/B
19.9x
Debt/Equity
0.0x
ROE
-25.0%
P/FCF
-18.4x
RSI (14)
—
ATR (14)
—
Beta
0.97
50d MA
$15.56
200d MA
$10.68
Avg Volume
1.3M
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
863 Mitten Road · South San Francisco, CA 94010 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.14 | -0.15 | -7.1% | 14.59 | +1.5% | +6.6% | — | — | — | — | — |
| Mar 12, 2026 | AMC | -0.14 | -0.15 | -7.1% | 16.01 | -1.6% | -4.3% | -1.8% | -3.5% | -12.1% | -12.0% | — |
| Nov 4, 2025 | AMC | -0.14 | -0.12 | +14.3% | 7.64 | -1.3% | -1.4% | +2.4% | -0.5% | +3.5% | +6.9% | — |
| Aug 7, 2025 | AMC | -0.13 | -0.10 | +23.1% | 4.13 | +1.5% | +4.4% | +5.8% | +9.0% | +21.1% | +17.4% | — |
| May 8, 2025 | AMC | -0.13 | -0.13 | +0.0% | 3.35 | +26.0% | +32.2% | +21.2% | +16.1% | +8.1% | +6.9% | — |
| Mar 25, 2025 | AMC | -0.12 | -0.18 | -50.0% | 3.93 | +1.8% | -14.8% | -14.2% | -14.0% | -19.1% | -19.3% | — |
| Nov 12, 2024 | AMC | -0.11 | -0.11 | +0.0% | 8.69 | +14.6% | +2.1% | -2.0% | -5.8% | -4.0% | -3.3% | — |
| Aug 6, 2024 | AMC | -0.12 | -0.07 | +41.7% | 3.00 | +6.7% | +9.7% | +19.7% | +32.3% | +22.7% | +25.3% | — |
| May 6, 2024 | AMC | -0.12 | -0.12 | +0.0% | 1.91 | -5.2% | -12.0% | +2.6% | +6.3% | +8.9% | +10.5% | — |
| Mar 19, 2024 | AMC | -0.14 | -0.14 | +0.0% | 1.96 | -2.0% | -5.6% | -6.1% | -8.7% | -10.2% | -10.2% | — |
| Nov 7, 2023 | AMC | -0.16 | -0.12 | +25.0% | 1.58 | +4.4% | +1.3% | -8.9% | -12.0% | -15.8% | -6.3% | — |
| Aug 8, 2023 | AMC | -0.14 | -0.14 | +0.0% | 2.14 | +0.5% | +7.9% | +0.0% | +4.7% | +4.2% | +0.9% | — |
| May 8, 2023 | AMC | -0.16 | -0.17 | -6.2% | 1.30 | +3.8% | +0.0% | +31.5% | +56.2% | +57.7% | +100.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.01 | $15.75 | -1.6% | -4.3% | -1.8% | -3.5% | -12.1% | -12.0% |
| Jan 22 | Jefferies | Maintains | Buy → Buy | — | $22.15 | $24.30 | +9.7% | +15.2% | +13.3% | +3.9% | -0.3% | -7.3% |
| Jan 21 | Barclays | Maintains | Overweight → Overweight | — | $21.41 | $21.76 | +1.6% | +3.5% | +19.2% | +17.2% | +7.5% | +3.1% |
| Jan 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $21.41 | $21.76 | +1.6% | +3.5% | +19.2% | +17.2% | +7.5% | +3.1% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.05 | $13.51 | +67.8% | +166.0% | +175.2% | +217.0% | +211.8% | +185.8% |
| May 20 | Mizuho | Maintains | Outperform → Outperform | — | $3.62 | $3.60 | -0.6% | +1.7% | +0.3% | -4.1% | -3.6% | +1.4% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.35 | $4.22 | +26.0% | +32.2% | +21.2% | +16.1% | +8.1% | +6.9% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.93 | $4.00 | +1.8% | -14.8% | -14.2% | -14.0% | -19.1% | -19.3% |
| Mar 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.93 | $4.00 | +1.8% | -14.8% | -14.2% | -14.0% | -19.1% | -19.3% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.20 | $5.18 | -0.4% | -1.9% | -5.4% | -9.0% | -3.7% | +0.4% |
| Nov 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.69 | $9.96 | +14.6% | +2.1% | -2.0% | -5.8% | -4.0% | -3.3% |
| Sep 16 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $5.10 | $5.25 | +2.9% | +13.3% | +7.8% | +7.5% | +10.0% | +15.9% |
| May 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.91 | $1.81 | -5.2% | -12.0% | +2.6% | +6.3% | +8.9% | +10.5% |
| Mar 27 | Mizuho | Maintains | Neutral → Neutral | — | $1.76 | $1.77 | +0.6% | +1.7% | +1.1% | +5.7% | +5.7% | -0.6% |
| Mar 20 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.96 | $1.92 | -2.0% | -5.6% | -6.1% | -8.7% | -10.2% | -10.2% |
| Sep 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.09 | $2.14 | +2.4% | -21.5% | -16.3% | -11.0% | -18.2% | -22.0% |
| Jun 16 | Mizuho | Maintains | Neutral → Neutral | — | $2.49 | $2.54 | +2.0% | -10.0% | -15.7% | -7.6% | -12.4% | -12.0% |
| May 30 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $2.60 | $2.75 | +5.8% | +18.8% | +16.9% | +24.6% | +23.1% | +26.2% |
| May 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.30 | $1.35 | +3.8% | +0.0% | +31.5% | +56.2% | +57.7% | +100.0% |
| Mar 30 | Mizuho | Maintains | Neutral → Neutral | — | $0.72 | $0.76 | +5.3% | +10.0% | +26.0% | +37.8% | +49.6% | +38.2% |
| Oct 7 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $0.88 | $0.94 | +6.3% | +6.3% | +5.0% | +4.1% | +5.1% | +2.9% |
| Dec 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.31 | $3.41 | +3.0% | -6.3% | -6.9% | -1.8% | +0.9% | -5.4% |
| Dec 1 | Jefferies | Maintains | Buy → Buy | — | $3.41 | $3.59 | +5.3% | -4.1% | -2.9% | -9.1% | -9.7% | -4.7% |
| Aug 3 | Mizuho | Maintains | Neutral → Neutral | — | $2.14 | $2.14 | +0.0% | -1.9% | -8.4% | -6.5% | -0.5% | -3.7% |
| Jul 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.33 | $2.10 | -9.9% | -0.9% | -6.4% | -1.3% | +0.4% | +0.9% |
| May 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.66 | $2.87 | +7.9% | +4.1% | +3.0% | +2.6% | +1.9% | +1.1% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.12 | $3.22 | +3.2% | -1.6% | -7.1% | -5.8% | -1.3% | +0.6% |
| Feb 10 | Mizuho | Downgrade | Buy → Neutral | — | $4.77 | $4.68 | -1.9% | -13.0% | -17.4% | -26.6% | -23.7% | -24.5% |
| Oct 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.86 | $4.71 | -3.1% | -14.2% | -13.4% | -16.9% | -17.9% | -19.3% |
| Mar 13 | Wedbush | Maintains | Outperform → Outperform | — | $2.47 | $2.44 | -1.2% | -2.8% | -29.6% | -23.1% | -28.7% | -19.0% |
| Mar 10 | H.C. Wainwright | Maintains | Buy → Buy | — | $2.72 | $3.02 | +11.0% | +2.9% | -0.4% | -9.2% | -11.8% | -36.0% |
| Sep 12 | Mizuho | Maintains | Buy → Buy | — | $4.15 | $4.46 | +7.5% | -8.2% | -10.1% | -13.5% | -18.6% | -17.8% |
| May 29 | Roth Capital | Maintains | Buy → Buy | — | $3.90 | $4.24 | +8.7% | -1.5% | -1.5% | -3.3% | +2.3% | +4.1% |
| Jun 5 | Jefferies | Maintains | Buy → Buy | — | $11.56 | $12.09 | +4.6% | +5.1% | +12.3% | +12.3% | +11.9% | +11.4% |
| Aug 24 | Credit Suisse | Upgrade | Underperform → Neutral | — | $13.00 | $14.03 | +7.9% | +12.8% | +11.9% | +11.9% | +17.2% | +22.3% |
| Aug 3 | Wedbush | Maintains | Outperform → Outperform | — | $11.84 | $12.31 | +4.0% | +1.9% | +3.5% | +2.8% | -1.6% | -4.6% |
| May 1 | Credit Suisse | Downgrade | Outperform → Underperform | — | $9.93 | $9.10 | -8.4% | -2.9% | +0.2% | -2.5% | -1.9% | +0.6% |
| Apr 19 | BTIG Research | Maintains | Buy → Buy | — | $15.03 | $14.87 | -1.1% | +1.1% | -0.2% | -0.1% | +0.7% | -1.1% |
| Apr 18 | Guggenheim | Maintains | Buy → Buy | — | $15.61 | $15.88 | +1.7% | -3.7% | -2.7% | -3.9% | -3.8% | -3.1% |
| Apr 18 | Credit Suisse | Maintains | Outperform → Outperform | — | $15.61 | $15.88 | +1.7% | -3.7% | -2.7% | -3.9% | -3.8% | -3.1% |
| Apr 18 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $15.61 | $15.88 | +1.7% | -3.7% | -2.7% | -3.9% | -3.8% | -3.1% |
No insider trades available.
8-K · 5.02
!!! Very High
Corvus Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Corvus Pharmaceuticals appointed Andrew C. Chan as a Class II director while Scott Morrison resigned, effective April 23, 2026, signaling potential strategic shifts in board leadership and oversight.
Apr 23
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
CRVS's equity issuance agreement with Jefferies suggests potential dilution for existing shareholders, though it may provide needed capital for operations or strategic initiatives.
Mar 13
8-K
Unknown — 8-K Filing
Curvepoint's positive Phase 1 atopic dermatitis data and $189M capital raise significantly extend runway, reducing dilution risk and improving odds of advancing soquelitinib through Phase 2 trials.
Mar 12
Data updated apr 25, 2026 3:25am
· Source: massive.com